We’re not a medical journal — but we believe customers and clinics deserve transparent pointers to published work. Here’s a careful, high-level look at what researchers have been studying.
Prefer the body-systems basics first? Read about the endocannabinoid system →
Researchers have studied CBD across several areas. Interest is high; evidence strength differs by topic.
Reviews of clinical and observational work discuss CBD’s potential relevance to pain-related quality of life, while also noting mixed results and the need for more rigorous trials. Topicals and oral products are not interchangeable in study design.
Example direction: systematic reviews indexed on PubMed examining CBD and pain outcomes (methods and conclusions vary by paper). Start at the PubMed CBD + pain reviews search.
Preclinical and some clinical literature explores how CBD may interact with inflammatory signaling. This is an active research area — promising for science, not a product claim.
Explore via PubMed: cannabidiol + inflammation.
Some clinical studies and reviews examine CBD in contexts related to anxiety symptoms. Doses, populations, and outcomes differ; this is not an indication for our topicals.
Reviews of CBD safety discuss generally favorable short-term tolerability in many studied settings, with attention to drug interactions, liver enzymes at higher oral doses, and product quality variability in the marketplace.
Quality tip: look for third-party testing / COAs when evaluating any CBD brand — including ours.
Oil, capsule, isolate, full/broad spectrum, or topical — results don’t always transfer across forms.
Study doses may be far from typical consumer use. Longer trials are still limited in many areas.
PubMed, clinical trial registries, and university summaries beat random social posts every time.
We use CBD as part of small-batch, all-natural-focused formulas made in the USA, designed for a comfortable sensory experience (no harsh burn, no strong smell).
We share research context so you can make informed choices — then we focus on quality manufacturing, transparent partnership conversations, and products people will actually keep using.